Wolverine Asset Management LLC Buys 227,222 Shares of Drugs Made In America Acquisition Corp. $DMAA

Wolverine Asset Management LLC raised its position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 22.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,249,128 shares of the company’s stock after purchasing an additional 227,222 shares during the period. Wolverine Asset Management LLC owned 4.28% of Drugs Made In America Acquisition worth $12,829,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in DMAA. Radcliffe Capital Management L.P. bought a new position in shares of Drugs Made In America Acquisition during the 2nd quarter worth $1,293,000. Boothbay Fund Management LLC purchased a new stake in Drugs Made In America Acquisition during the second quarter valued at about $5,814,000. Shaolin Capital Management LLC bought a new position in Drugs Made In America Acquisition during the second quarter worth about $1,020,000. Karpus Management Inc. increased its stake in shares of Drugs Made In America Acquisition by 18.1% in the second quarter. Karpus Management Inc. now owns 2,744,109 shares of the company’s stock worth $27,990,000 after purchasing an additional 420,075 shares in the last quarter. Finally, Clear Street LLC purchased a new stake in shares of Drugs Made In America Acquisition during the 2nd quarter valued at approximately $1,149,000.

Drugs Made In America Acquisition Price Performance

DMAA stock opened at $10.40 on Friday. The firm’s 50-day moving average is $10.35. Drugs Made In America Acquisition Corp. has a twelve month low of $9.95 and a twelve month high of $10.41.

Drugs Made In America Acquisition (NASDAQ:DMAA) last released its quarterly earnings data on Tuesday, November 18th. The company reported $0.07 EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.